Declines in US Overdose Deaths Compared to Exponential Predictions

Joseph R. Friedman, MD, PhD, MPH[1*], Joseph J. Palamar, PhD[2], Daniel Ciccarone, MD, MPH[3], Tommi L. Gaines, DrPH[4], Annick Borquez, PhD[4], Chelsea L. Shover, PhD[5], Steffanie A. Strathdee, PhD[4]

[1]Department of Psychiatry, University of California, San Diego, San Diego, CA
[2]Department of Population Health, NYU Grossman School of Medicine, New York, NY
[3]Department of Family Community Medicine, University of California, San Francisco, San Francisco, CA
[4]Department of Medicine, University of California, San Diego, San Diego, San Diego, CA
[5]Department of Medicine, University of California, Los Angeles, Los Angeles, CA

*Correspondence to:
Joseph Friedman, MD, PhD, MPH, University of California, San Diego, 200 W Arbor Dr, San Diego, CA, 92103. jofriedman@health.ucsd.edu

Word Count: 600 words

Abstract

Introduction: After decades of growth described nearly perfectly with an exponential curve, US overdose mortality has begun to decrease. Here we aim to determine whether decreases in overdose mortality between 2023 and 2024 deviate from a previously defined exponential growth curve.

Methods: This observational study examined overdose deaths in the US between January 1980-December 2024. Mortality trends were compared to an exponential growth curve, fit on data from 1979 to 2016.

Results: After precipitously surpassing exponential growth predictions in 2020-2023, overdose deaths fell sharply from approximately 32 per 100,000 in 2021-2023 to 23.7 in 2024, below the lower bound of the exponential curve prediction (24.98) for the first time since 2001. Decreases reflected declining illicit fentanyl-involved deaths (with and without stimulants); however, deaths involving stimulants without fentanyl, and those involving xylazine, continued to increase in 2024.

Conclusions and Relevance: Recent decreases in overdose deaths are encouraging, unprecedented, and represent the first significant, large-magnitude deviation below exponential growth. However, policymakers, clinicians, and public health officials should be prepared for the possibility that a resurgence could occur, especially if novel synthetic drugs change the risk environment of illicit drug use. Stimulants and xylazine continue to represent increasingly important public health challenges.

Main Text

Introduction

US overdose deaths have been driven by a shifting profile of drugs over time, often described through a four-wave paradigm[1]. Waves 1-4 correspond to deaths from prescription opioids, heroin, fentanyl without stimulants, and fentanyl with stimulants, respectively[2]. Although deaths from individual drug classes have risen and fallen, Jalal et al. showed that they cumulatively added to a virtually-mathematically-perfect exponential growth curve between 1979-2016.[3] Subsequent deviations above this curve have occurred[4]; however, large-magnitude shifts below it have not been demonstrated. Given that US overdose death rates began decreasing in mid-2023,[5] we assess if overdose mortality remains consistent with an overall exponential growth pattern.

Methods

Nationally representative drug overdose death data were obtained from the National Vital Statistics System for 1979-2024 using ICD-10 underlying cause of death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined), overall and by substance-involvement, for prescription opioids (T40.2), heroin (T40.1), synthetic opioids (primarily and herein referred to as fentanyl) [T40.4], cocaine (T40.5), psychostimulants with abuse potential (primarily and herein referred to as methamphetamine) [T43.6], and xylazine (T42.7 or T46.5)[eMethods]. To recreate the exponential growth curve defined by Jalal et al.[3] we regressed the natural log of deaths per 100,000 population against continuous year (1979-2016) with predictions and 95% confidence intervals extrapolated through 2024. Analyses were

conducted in R version 4.4.1. This analysis was exempt from review by the University of California, San Diego institutional review board.

Results

During the COVID-19 pandemic in 2020, overdose mortality rose sharply above the exponential growth curve (Figure). Rates remained elevated above the curve prediction, at approximately 32 deaths per 100,000 population between 2021 and 2023. In 2024, national overdose mortality fell precipitously to 23.7 per 100,000, dropping below the 95% confidence interval of the exponential curve prediction (24.1-29.0 per 100,000) for the first time since 2001.

Rates of overdose deaths involving prescription opioids (with fentanyl co-involved deaths omitted), heroin (fentanyl omitted), fentanyl (without stimulants), and fentanyl (with stimulants) reached inflection points and began to fall in 2016, 2015, 2022, and 2024, respectively, marking the decline of waves 1-4 of the crisis, respectively. Deaths involving methamphetamine (without fentanyl) and cocaine (without fentanyl) increased between 2023 and 2024. Deaths involving xylazine also rose and represented an increasing proportion of fentanyl-involved deaths (8.3% in 2023 vs 12.6% in 2024).

Discussion

The US is in the midst of a historic moment in the trajectory of the overdose crisis. Our findings suggest that the downward trends observed in 2023-2024 represent the first sustained, high-magnitude departure below the exponential growth curve that characterized the crisis for nearly half a century prior.[3,4] All four waves of the overdose crisis are now in decline, with wave

four (fentanyl with stimulants) beginning to reverse in 2024. Limitations of this study include the provisional nature of 2024 data.

The degree to which these decreases reflect changes in drug potency, tolerance, use practices, and/or policies remains to be determined, but their permanence will depend on future shifts across these factors. Policymakers, clinicians, and public health officials should be prepared for the possibility of a return to exponential growth, especially if novel synthetic drugs once again change the risk environment of drug use. Of note, deaths involving stimulants (without fentanyl) and xylazine are still increasing, highlighting that the nature of the crisis continues to present new public health challenges requiring updated interventions. Furthermore, despite progress, overdose death rates remain at about 400% of the magnitude seen in the year 2000 and continue to be far higher than those in other developed nations.[6] The nearly 80,000 lives lost to overdose in 2024 remain a staggering quantity of preventable mortality.

Funding

JRF received funding from the National Institute on Drug Abuse (DA049644; U01DA063078) and the National Institute of Mental Health (MH101072). JP received support from the National Institute on Drug Abuse of the National Institutes of Health (R01DA057289 and U01DA051126). DC received funding from the National Institute on Drug Abuse (R01DA054190 and R21DA064011). CLS was supported by National Institute on Drug Abuse (R01DA057630; K01DA05771**).** AB was supported by National Institute on Drug Abuse (R33DA061260 and DP2DA049295). SAS received funding from the National Institute of Drug Abuse (U01DA063078; R33DA061260). Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflicts of Interest

JP reported receiving personal fees from the Washington-Baltimore High Intensity Drug Trafficking Areas program, Elsevier, Wiley, Rutgers University, Arizona State University, the University of Southern California, Queensland University, the National Network of Public Health Institutes, Alta Mira Recovery programs, and Dartmouth University, and nonfinancial support from NIH/NIDA, the University of Florida, Rx Summit, the American College of Neuropsychopharmacology, and the Reagan-Udall Foundation for the FDA during the conduct of the study. DC reports personal fees from Celero Systems and Motley-Rice LLC outside the submitted work. All other authors declare no conflict of interest.



Figure. Overdose Death Rates Compared to Exponential Growth and by Substance Co-Involvement
A) National-level estimates of overdose deaths per 100,000 are shown by year from 1979 to 2024. Following the general approach established by Jalal et al., an exponential line of best fit is shown, estimated using data from 1979-2016 with a 95% uncertainty interval. The vertical dashed line shows the portion of the graph corresponding to Figure part B, for which drug-specific data were available from 1999-2024. B) Drug overdose death rates per 100,000 are shown by specific substance involvement. Fentanyl-involved deaths are shown separately by stimulant co-involvement status. *Deaths for methamphetamine (meth), cocaine, commonly prescribed opioids (Rx Opioids) and heroin are shown removing deaths co-involved with fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.

121

References

1. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*. 2021;34(4):344-350. doi:10.1097/YCO.0000000000000717

2. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. *Addiction*. 2023;118(12):2477-2485. doi:10.1111/add.16318

3. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*. 2018;361(6408):eaau1184. doi:10.1126/science.aau1184

4. Jalal H, Burke DS. Exponential growth of drug overdose poisoning and opportunities for intervention. *Addiction*. 2022;117(5):1200-1202. doi:10.1111/add.15841

5. Post LA, Ciccarone D, Unick GJ, et al. Decline in US Drug Overdose Deaths by Region, Substance, and Demographics. *JAMA Netw Open*. 2025;8(6):e2514997. doi:10.1001/jamanetworkopen.2025.14997

6. Gumas E. *U.S. Overdose Deaths Remain Higher Than in Other Countries — Trend-Tracking and Harm-Reduction Policies Could Help*. Commonwealth Fund; 2025. https://www.commonwealthfund.org/blog/2025/us-overdose-deaths-remain-higher-other-countries-trend-tracking-and-harm-reduction